

## 승모판 일탈 증후군의 증상에 따른 심박 변동성

신 영 우

### Heart Rate Variability Related to Symptoms in Patients with Mitral Valve Prolapse Syndrome

Yung Woo Shin, MD

Division of Cardiology, Department of Internal Medicine Pusan National University Hospital, Busan, Korea

#### ABSTRACT

**Background and Objectives** : Studies in patients with mitral valve prolapse syndrome (MVPS) have shown a variety of forms of autonomic dysfunction, which require further investigation. **Subjects and Methods** : The study group consisted of 29 male MVP patients, aged  $23 \pm 3$  years, and 17 male healthy controls, aged  $25 \pm 2$  years. The patients and the control subjects were matched for age and sex. All study subjects underwent a complete echocardiographic examination, and were free of other organic heart diseases and arrhythmia. In a prospective study, the heart rate variability (HRV) indices were calculated from 24-hour Holter recordings, obtained during normal daily activity, and plasma norepinephrine levels measured, and the data between the patients and the controls compared to quantify the autonomic activity. **Results** : The HRV indices were significantly greater in the patient than the controls, and revealed hypervagal and mixed type in 55.2 and 20.7% of patients, respectively. There was the greatest parasympathetic activity in the MVPS patients with presyncope or syncope. The MVPS patients with palpitation tended to show hypersympathetic activity, as in the mixed type. **Conclusion** : Our data suggests that MVPS patients exhibit autonomic dysfunction, mostly resulting from parasympathetic hyperresponsiveness. (Korean Circulation J 2002;32(12):1078-1084)

**KEY WORDS** : Electrocardiography, ambulatory ; Mitral valve prolapse ; Disorders of the autonomic nervous system.

#### 서 론

<sup>1)</sup>

가 가 가 <sup>1-4)</sup>

가 , 가 ,

: 2002 8 27

: 2002 10 21

: , 602 - 739 1가 10

<sup>5-7)</sup>

: (051) 244 - 1970 · : (051) 241 - 4933

E - mail : pnushsin@hanmail.net

가

가

ANOVA

Dunnett t - test(2 sided)

Scheffe

0.05

대상 및 방법

20~29

17

25 ± 2

29

23 ± 3

24

Holter

SONOS 5500

2

2 mm

M - mode

2 mm

가

Holter

cassette

Del-

mar Avionics 750A Innovator

가

17

norepinephrine

, High - Performance Liquid Chromatography

1) 24

(mHR). 2) 24

(SDNN). 3) 5

(SDANN). 3)

(rMSSD). 4)

50 ms

가

(pNN50). 5) rMSSD

(rMSSD - Dif)

7

30

9

30

t - test

결 과

승모판 일탈 증후군의 심박 변동성

79 ± 7

76 ± 8

(p = 0.101), SDNN

146 ± 22 ms

179 ± 44 ms(p = 0.003), SDANN

138 ± 24 ms

165 ± 44 ms(p = 0.012), rMSSD

30 ± 5 ms

42 ± 13 ms(p = 0.000), rMSSD - Dif

13 ± 9 ms

21 ± 13 ms(p = 0.009)

pNN50

9 ± 4%

18 ± 9%(p = 0.000)

, SDNN, SDANN, rMSSD, r - MSSD - Dif, pNN50

가

(Table 1).

승모판 일탈 증후군의 증상에 따른 심박 변동성

1

2

3

**Table 1.** Comparison of heart rate and heart rate variability indices between healthy subjects and patients with mitral valve prolapse syndrome (MVPS)

Measure	Healthy subjects (n = 17)	MVPS (n = 29)	p
Mean HR (bpm)	79 ± 7	76 ± 8	.101
SDNN (ms)	146 ± 22	179 ± 44	.003
SDANN (ms)	138 ± 24	165 ± 44	.012
rMSSD (ms)	30 ± 5	42 ± 13	.000
rMSSD-Dif (ms)	13 ± 9	21 ± 13	.009
pNN50 (%)	9 ± 4	18 ± 9	.000

Values are means ± SD. HR : heart rate, SDNN : the standard deviation (SD) of normal-to-normal R-R intervals, SDANN : SD of 5min averages of normal-to-normal R-R intervals, rMSSD : the root-mean square of the difference of successive normal, R-R intervals, rMSSD-Dif : difference between night time and day time rMSSD, pNN50 : % of the differences between adjacent normal R-R intervals > 50 ms

, SDNN, SDANN, rMSSD, rMSSD - Dif  
 pNN50 . 1 29 22  
 SDNN(p=0.003), SDANN(p=0.004), rMSSD(p=0.001), rMSSD - Dif(p=0.000)  
 rMSSD - Dif가 95%  
 18 ms  
 22 6  
 2 SDNN(p=0.021), 20.7% ,  
 rMSSD(p=0.015) pNN50(p=0.010) 16 55.2% .  
 3 pNN50(p=0.016)  
 55.2% 20.7%  
 1 가 (Table 3, 4).

2 , 3 승모판 일탈 증후군에서 주증상에 따른 자율신경 활성도의  
 가 가 (Table 2). 특성

rMSSD-Dif와 자율신경 활성도의 관계 가  
 rMSSD - Dif norepinephrine rMSSD  
 norepinephrine F 2.86  
 (p=0.09) F 3.34(p=0.05) J norepinephrine 9 5 ,  
 , rMSSD norepinephrine 4 3 가  
 15 10 가  
 가 rMSSD - Dif  
 , norepinephrine  
 가 rMSSD - Dif  
 , rMSSD 가  
 rMSSD - Dif

승모판 일탈 증후군에서 자율신경 활성도의 양상  
 rMSSD  
 95% 33 ms

**Table 3.** Frequency of patients with mitral valve prolapse syndrome according to rMSSD and rMSSD-Dif

	rMSSD		Total
	33 ms*	<33 ms	
rMSSD-Dif	18 ms <sup>†</sup>	16	0
	<18 ms	6	7
Total	22	7	29

Abbreviations as in Table 1. \* : 95% confidence upper bound for rMSSD in the healthy control, † : 95% confidence upper bound for rMSSD-Dif in the healthy control

**Table 2.** Comparison of heart rate and heart rate variability indices between healthy subjects and patients with mitral valve prolapse syndrome (MVPS) according to the chief symptoms

Measure	Healthy subjects (n = 17)	MVPS		
		Group 1 (n = 5)	Group 2 (n = 8)	Group 3 (n = 16)
Mean HR (bpm)	79 ± 7	72 ± 6	75 ± 9	78 ± 8
SDNN (ms)	146 ± 22	209 ± 54 <sup>†</sup>	189 ± 60*	164 ± 24
SDANN (ms)	138 ± 24	200 ± 56 <sup>†</sup>	171 ± 56	152 ± 26
rMSSD (ms)	30 ± 5	51 ± 12 <sup>†</sup>	44 ± 15*	39 ± 12
rMSSD-Dif (ms)	13 ± 9	41 ± 8 <sup>‡</sup>	14 ± 6	18 ± 9
pNN 50 (%)	9 ± 4	22 ± 8 <sup>†</sup>	19 ± 11*	16 ± 9*

Abbreviations as in Table 1. Values are means ± SD. Statistical significance versus healthy subjects, \* : p<0.05, † : p<0.01, ‡ : p<0.001. Group 1 : MVPS with near syncope or syncope, Group 2 : MVPS with palpitation, Group 3 : MVPS with chest pain

8)

## 가 ,

9)

.

가 가

10)

가

• ,

61.8~

98.7% 11)

가 12) 가

13)14)

•

24

14) R - R R - R

R - R 가 ,

NN R - R R - R

, SDANN

SDANN

SDNN

R - R

R-R

R - R  
. R - R  
pNN50  
R - R  
R - R  
, pNN50  
<sup>14)</sup>  
가  
가 21.8~68.9%,  
13~23%,  
12.5~22.6%  
<sup>5)6)</sup>  
<sup>14)15)</sup>  
10  
20~30 가 <sup>1)</sup>  
<sup>7)</sup> 20~29  
<sup>16)</sup>  
가 , 6  
terenol  
norepinephrine  
<sup>23)24)</sup>  
norepinephrine  
<sup>25)</sup>  
norepinephrine  
가 , isopro-  
가  
<sup>1)</sup> Lichodziejewska <sup>26)</sup>  
63% norepinephrine  
<sup>1)3)4)</sup>  
. Coghlan  
norepinephrine  
<sup>17)</sup>  
33%, 10%  
54% 가  
norepinephrine 17 350 pg/mL  
<sup>27)</sup> 4 . rMSSD  
rMSSD - Dif  
<sup>19)</sup> Ewing <sup>18)</sup> 5  
가 20.7%  
rMSSD rMSSD - Dif  
<sup>28)</sup>  
Dif norepinephrine  
rMSSD rMSSD - Dif  
52%,  
4%,  
가 가 8% . Frisin-  
ghelli <sup>20)</sup> 가  
, tilt  
가  
가  
<sup>22)</sup>  
<sup>1)</sup> norepinephrine

가 가

가

가

요 약

배경 및 목적 :

방 법 :

17 ( 25 ± 2 )

29 ( 23 ± 3 )

24 Holter

norepinephrine

결 과 :

55.2%

20.7%

가

가

결 론 :

가

가

중심 단어 :

## REFERENCES

- Fontana ME, Sparks EA, Boudoulas H, Wooley CF. Mitral valve prolapse and the mitral valve prolapse syndrome. *Curr Probl Cardiol* 1991;16:309-75.
- Kautzner J. Heart rate variability in patients with mitral valve prolapse. In: Malik M, Camm AJ, editor. *Heart Rate Variability*. New York: Futura Publishing Co;1995. p.500.
- Braunwald E. Mitral valve prolapse syndrome. In: Braunwald E, Zipes DP, Libby P, editor. *Heart Disease*. 6th ed. Philadelphia: W.B. Saunders Co.;2001. p.1665-71.
- Devereux RB. Mitral valve prolapse. In: Crawford MH, DiMarco JP, editor. *Cardiology*. 1st ed. Mosby;2001. 6.1-6.10.
- Tsuji H, Venditti FJ Jr, Manders ES, Evans JC, Larson MG, Feldman CL, Levy D. Determinants of heart rate variability. *J Am Coll Cardiol* 1996;28:1539-46.
- Singh JP, Larson MG, O'Donnell CJ, Tsuji H, Evans JC, Levy D. Heritability of heart rate variability. *Circulation* 1999;99:2251-4.
- Fagard RH, Pardaens K, Staessen JA. Influence of demographic, anthropometric and lifestyle characteristics on heart rate and its variability in the population. *J Hypertens* 1999;17:1589-99.
- Malik M, Camm AJ. Components of heart rate variability: what they really mean and what we really measure? *Am J Cardiol* 1993;72:821-2.
- Boudoulas H, Kolibash AJ Jr, Baker P, King BD, Wooley CF. Mitral valve prolapse and the mitral valve prolapse syndrome: a diagnostic classification and pathogenesis of symptoms. *Am Heart J* 1989;118:796-818.
- Stefanadis C, Toutouzas P. Mitral valve prolapse: the merchant of venice or much ado about nothing? *Eur Heart J* 2000;21:255-8.
- Flack JM, Kvasnicka JH, Gardin JM, Gidding SS, Manolio TA, Jacobs DR Jr. Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults. *Am Heart J* 1999;138:486-92.
- Devereux RB, Kramer-Fox R, Brown WT, Shear MK, Hartman N, Kligfield P, Lutas EM, Spitzer MC, Litwin SD. Relation between clinical features of the mitral prolapse syndrome and echocardiographically documented mitral valve prolapse. *J Am Coll Cardiol* 1986;8:763-72.
- Malik M. Heart rate variability. *Curr Opin Cardiol* 1998;13:36-44.
- Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standard of measurement, physiological interpretation, and clinical use. *Circulation* 1996;93:1043-65.
- Huikuri HV, Makikallio T, Airaksinen KE, Mitrani R, Castellanos A, Myerburg R. Measurement of heart rate variability: a clinical tool or a research toy? *J Am Coll Cardiol* 1999;34:1878-83.
- Zuppiroli A, Roman MJ, O'Grady M, Devereux RB. A family study of anterior mitral leaflet thickness and mitral valve prolapse. *Am J Cardiol* 1998;82:823-6.
- Coghlan HC, Phares P, Crowley M, Copley D, James TN. Dysautonomia in mitral valve prolapse. *Am J Med* 1979;67:236-44.
- Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. *Br Med J* 1982;285:916-8.
- Chun KJ, Kim JH, Ko WS, Hong TJ, Shin YW, Shin YK. The evaluation of autonomic dysfunction in patients with mitral valve prolapse. *Korean Circ J* 1994;24:458-65.
- Frisinghelli A, Turiel M, Milletich A, Crema C, Malliani A. The role of mitral regurgitation in the neurovegetative regulation of mitral valve prolapse. *Cardiologia* 1992;37:781-3.
- Kozłowski JW, Trzos S, Rezentryt P, Jozwiak Z, Trzos E,

- Maciejewski M, Moczak R, Leszczynski S. *Spectral analysis of heart rate variability in patients with mitral valve prolapse [Abstr]. Eur Heart J 1992;13 (Suppl):407.*
- 22) Shin YW. *Mitral valve prolapse syndrome. Korean Circ J 2001;31:735-8.*
  - 23) Tygesen H, Rundqvist B, Waagstein F, Wennerblom B. *Heart rate variability measurement correlates with cardiac norepinephrine spillover in congestive heart failure. Am J Cardiol 2001;87:1308-11.*
  - 24) Grassi G, Esler M. *How to assess sympathetic activity in humans. J Hypertens 1999;17:719-34.*
  - 25) Breuer HW, Skyschally A, Schulz R, Martin C, Wehr M, Heusch G. *Heart rate variability and circulating catecholamine concentrations during steady state exercise in healthy volunteers. Br Heart J 1993;70:144-9.*
  - 26) Lichodziejewska B, Klos J, Rezler J, Grudzka K, Dlu-zniewska M, Budaj A, Ceremuzynski L. *Clinical symptoms of mitral valve prolapse are related to hypomagnesemia and attenuated by magnesium supplementation. Am J Cardiol 1997;79:768-72.*
  - 27) Landsberg L, Young JB. *Physiology and pharmacology of the autonomic nervous system. In: Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw-Hill Company;2001. p.441.*
  - 28) Shin YW, Oah HM, Kim JW, Hong TJ. *Heart rate variability in mitral valve prolapse syndrome. Korean Circ J 1998;28:1973-80.*